Yahoo
NYSE - Delayed Quote USD

Enovis Corporation (ENOV)

18.56 -0.84 (-4.33%)
At close: September 4 at 4:00:02 PM EDT
18.59 +0.03 (+0.16%)
After hours: September 4 at 7:58:11 PM EDT
Trade Enovis on Coinbase
Chart Range Bar
Loading chart for ENOV
  • Previous Close 19.40
  • Open 19.01
  • Bid 18.64 x 40000
  • Ask 18.74 x 30000
  • Day's Range 18.52 - 19.32
  • 52 Week Range 18.52 - 34.28
  • Volume 1,886,159
  • Avg. Volume 1,208,179
  • Market Cap (intraday) 1.07B
  • Beta (5Y Monthly) 1.43
  • PE Ratio (TTM) --
  • EPS (TTM) -18.44
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 38.33

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

www.enovis.com

7,802

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ENOV
30.33%
S&P 500 (^GSPC)
12.75%

1-Year Return

ENOV
41.17%
S&P 500 (^GSPC)
18.71%

3-Year Return

ENOV
67.15%
S&P 500 (^GSPC)
70.93%

5-Year Return

ENOV
77.81%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 582.78M
Earnings -1.19M
Profit Margin -0.20%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-400M
-200M
0
200M
400M
-100.0%
-80.0%
-60.0%
-40.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

24.00
38.33 Average
18.56 Current
52.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 39 -> 33

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    1.12B

  • Enterprise Value

    2.48B

  • Trailing P/E

    --

  • Forward P/E

    4.94

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.48

  • Price/Book (mrq)

    0.76

  • Enterprise Value/Revenue

    1.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -47.97%

  • Return on Assets (ttm)

    1.19%

  • Return on Equity (ttm)

    -54.14%

  • Revenue (ttm)

    2.3B

  • Net Income Avi to Common (ttm)

    -1.1B

  • Diluted EPS (ttm)

    -18.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.56M

  • Total Debt/Equity (mrq)

    92.55%

  • Levered Free Cash Flow (ttm)

    185.57M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

18.56 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Lowering target price to $20.00

    ENOVIS CORP has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
  • What does Argus have to say about ENOV?

    ENOVIS CORP has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
  • Raising target price to $27.00

    ENOVIS CORP has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
  • Lowering target price to $23.00

    ENOVIS CORP has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: